About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

The event aimed to strengthen the bond among those affected with thalassemia along with the dedicated medical and support ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

News on Telangana Today, Thalassemia & Sickle Cell Society (TSCS) latest news, Thalassemia & Sickle Cell Society (TSCS) news, | Telangana Today ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Celebrating 14 years of dedicated healthcare, Fernandez Hospital, Hyderguda, in collaboration with the Thalassemia and Sickle ...

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.